Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01106950 · ClinicalTrials.gov registry record · Phase 2
Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT01106950 is a Phase 2 study that was terminated before completion, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 15 participants.
The verdict
NCT01106950, a Phase 2 study, was terminated before completion, sponsored by Masonic Cancer Center, University of Minnesota.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a phase II therapeutic study of related donor HLA-haploidentical NK-cell based therapy after a high dose of fludarabine/cyclophosphamide with denileukin diftitox preparative regimen for the treatment of poor prognosis acute myelogenous leukemia (AML).
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- BIOLOGICAL Natural Killer Cells
- DRUG Denileukin diftitox
- PROCEDURE Donor lymphapheresis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2010-07 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01106950
The ClinicalTrials.gov registry entry for NCT01106950 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT01106950 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01106950 about?
NCT01106950 is a clinical study titled "Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)". This is a phase II therapeutic study of related donor HLA-haploidentical NK-cell based therapy after a high dose of fludarabine/cyclophosphamide with denileukin diftitox preparative regimen for the treatment of poor prognosis acute myelogenous leukemia (AML).
What is the current status of trial NCT01106950?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2010-07. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01106950?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Natural Killer Cells (BIOLOGICAL), Denileukin diftitox (DRUG), Donor lymphapheresis (PROCEDURE).
Who is sponsoring clinical trial NCT01106950?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.